130 results about "Somatic antigen" patented technology

The invention belongs to the field of biological detection, and discloses a kit for detecting cervical cancer and application of the kit. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the heavy chain amino acid sequence of the monoclonal antibody CPT1A-1 of the anti-CPT1A protein in the capture antibody is as shown in SEQ ID NO. 1, and the light chain amino acid sequence is as shown in SEQ ID NO. 2; the heavy chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.4. The kit for diagnosis of cervical cancer provided by the invention has strong specificity, can specifically detect the content of CPT1A protein in serum, has good stability, and has good application prospects.

The invention discloses an mRNA (messenger ribonucleic acid) transcription skeleton vector and application thereof in preparation of a self-amplification type mRNA vaccine, and belongs to the technical field of veterinary biological products. According to the invention, alphavirus non-structural protein regions NSP2 and NSP3 of a self-amplification type mRNA skeleton are modified, a polyA tail is optimized, and a novel self-amplification type mRNA skeleton is constructed; the self-amplification type mRNA vaccine can improve the antigen expression efficiency, reduce the toxicity of non-structural protein to cells and improve the encapsulation efficiency and delivery efficiency by combining with the optimization of the components and proportion of a lipid nano delivery system, and meanwhile, the self-amplification type mRNA vaccine is wide in applicable pathogen antigen range and can be popularized to more animal epidemic diseases. The characteristics of high-efficiency expression, low-toxicity delivery and single-dose immunization are expected to renovate the immunization strategy of the existing animal vaccine, the epidemic prevention cost of the breeding industry is reduced, and the method has a wide industrial application prospect.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a detection kit and a detection method for a pretumor marker. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the capture antibody and the HRP labeled antibody are both prepared from a monoclonal antibody of the anti-SLC31A1 protein. According to the detection method of the kit for detecting the pretumor marker, the SLC31A1 protein content in human serum is detected through the kit, the specificity is high, a large batch of samples can be rapidly detected in a high-throughput mode, the cancer risk of a to-be-detected crowd can be effectively judged, and therefore relevant patients can find and treat the pretumor marker in advance, treatment prognosis is improved, and the death rate is reduced.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

The invention provides an antibody screening method and system based on a differential evolution algorithm and an artificial intelligence model. The method comprises the following steps: S1, acquiring data of an antibody-antigen compound sequence and affinity; s2, encoding the antibody and antigen sequences by using a language model, and converting the encoded antibody and antigen sequences into a matrix M; s3, training a machine learning model by using the matrix M and the affinity parameters to obtain a trained optimal machine learning model; s4, predicting the antigen affinity of the antibody by utilizing the trained optimal machine learning model; and S5, carrying out affinity optimization on the antibody sequence based on a differential evolution algorithm, and carrying out further filtration by predicting the druggability of the antibody so as to screen the antibody with high affinity and good drug properties.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention provides preparation of a novel O antigen and specific serum of vibrio parahaemolyticus. The classification name of the vibrio parahaemolyticus is vibrio parahaemolyticus O17: K4, and the preservation number of the vibrio parahaemolyticus O17: K4 is CGMCC (China General Microbiological Culture Collection Center) No.31706. The invention further discloses a preparation method of the vibrio The novel thallus antigen O17 vibrio parahaemolyticus is determined by adopting an agglutination reaction and a whole genome sequencing method of existing diagnostic serum (11 kinds of O) of the vibrio parahaemolyticus. The novel O17 specific serum is obtained through preparation of a novel thallus antigen O17, animal immunization and adsorption separation. The novel O17 specific serum prepared by the invention is high in sensitivity and strong in specificity, can be conveniently and quickly used for detecting a brand new novel thallus antigen O17 vibrio parahaemolyticus which is prevalent in recent years, and provides an important detection technology for pathogen confirmation, monitoring and prevention and control of infectious diarrhea and food-borne diseases in laboratories.

The invention relates to a kit for detecting plasma cells and related antibody levels in a thymus microenvironment and application of the kit. The kit comprises a quantum dot labeled antibody CD138, a quantum dot labeled antibody CD21, a quantum dot labeled AchR, Musk and / or LRP4 receptor, an antigen repair solution and a DNA fluorescent dye solution, wherein the quantum dot labeled antibody CD138, the quantum dot labeled antibody CD21, the quantum dot labeled AchR, the quantum dot labeled Musk and / or the quantum dot labeled LRP4 receptor, the antigen repair solution and the DNA fluorescent dye solution; through the kit, one or more of plasma cells, follicular DC and related antibodies in a thymus (tumor) sample can be detected, so that the immune level of a tissue slice sample is obtained. A method of carrying the antibody by using the quantum dots is adopted, so that a secondary antibody dyeing link in the existing multicolor immunofluorescence technology is omitted, and the efficiency is improved; the quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of plasma cells and follicular DCs in the thymoma tumor microenvironment is achieved, and both quantity detection and position detection can be achieved.

Provided is a nanovaccine. The nanovaccine is prepared from the following starting materials: a sustained-release carrier, an antigen, an adjuvant, and a cationic component. The mass ratio of the sustained-release carrier to the antigen to the adjuvant to the cationic component is (1-30):1:(0.1-1):(0.05-0.5). The sustained-release carrier comprises sodium alginate. The antigen comprises at least one of a protein, a recombinant subunit, and a polypeptide. The cationic component comprises at least one of a calcium ion, a manganese ion, an aluminum ion, a polyamine, a basic amino acid, and a polyamino acid consisting of 2-30 basic amino acids. The nanovaccine comprises the sustained-release carrier sodium alginate, the antigen, the adjuvant, and the cationic component in a proper ratio. Sodium alginate is used as a sustained-release carrier and is promoted to form a network structure under the action of the cationic component, so as to encapsulate the antigen and the adjuvant, thereby forming a stable antigen-carrier-adjuvant nanoparticle gel. The nanovaccine can induce a stronger immune response and has good stability and good biocompatibility.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention discloses an unknown network threat immunodetector generation method and device, and relates to the technical field of network security, and the method comprises the steps: S1, obtaining a training sample; s2, performing antigen presentation to obtain a training autoantigen set and a training non-autoantigen set; s3, extracting an edge autoantigen; s4, deducing an unknown non-autologous antigen by using the edge autoantigen; s5, carrying out tolerance training on unknown non-autoantigen and autoantigen, adding the antigen subjected to tolerance training as a mature antibody into the t-th generation non-autoantigen set, and generating a network attack detector; s6, judging whether t reaches a preset number of times, and if so, ending; otherwise, entering S7; s7, enabling t + 1 to be equal to t, and returning to S3; according to the method, the autoevolution of the detector is realized, and the immune detector capable of detecting unknown is generated, so that the immune detector can dynamically adapt to an unknown network attack mode; according to the method, an edge benign detector can adaptively optimize and construct an unknown attack process, and unknown network threats can be efficiently and accurately detected.

This disclosure provides an anti-5T4 antigen-binding domain that can be incorporated into antibodies and receptors, including a bispecific anti-5T4 antibody, a biparatopic anti-5T4 antibody, and its antibody-drug conjugate, comprising a first antigen-binding domain that specifically binds to a first 5T4 epitope, a second antibody-antigen-binding domain that specifically binds to a second 5T4 epitope that is not identical to the first 5T4 epitope (the first antigen-binding domain is operably linked to the second antigen-binding domain), and a chemotherapeutic agent. This disclosure further provides methods for using it for the treatment of cancer.

The present invention provides the preparation, epitope identification and application of a PRRSV non-structural protein 12 antibody. By constructing a eukaryotic expression vector pCDNA3.4-Nsp12-strep, transiently transfecting CHO cells, and purifying the PRRSV Nsp12 recombinant protein using the downstream strep tag, the purified Nsp12 is used as an antigen to immunize Balb / C mice. The spleen cells of the mice are isolated, and single specific B cells are separated by the FACS method. The antibody variable region sequences of the single B cells are obtained by RT-PCR. Recombinant expression plasmids of the heavy chain and light chain are constructed respectively, transfected into CHO suspension cells, expressed, and 2 complete anti-PRRSV Nsp12 monoclonal antibodies 1N14 and 2S18 are obtained by Protein G purification. The application scopes of the 1N14 and 2S18 antibodies and the specific antigen epitope recognized by the 1N14 antibody are further determined, and its sequence is 104 YEFTGNGEDW 113 。

The present disclosure relates to anti-TFR1 (transferrin receptor 1) antibodies, antigen binding fragments and uses thereof.

The invention relates to the technical field of antibody detection, and discloses a canine entomophilous disease quintuplet antibody detection card, a preparation method thereof and a kit. The detection card comprises the following five detection antigens a)-e): a) a leishmania antigen which is fusion protein of rk39, rk26 and rk9; b) a babesia antigen which is a fusion protein of TRAP and rBcMSA1 / rBcSA1; c) an amorphous antigen which is a fusion protein of P44 and OMP-1X; the detection card and the kit have the advantages that joint detection of IgG (immunoglobulin G) and IgM (immunoglobulin M) antibodies corresponding to canine Ehrlichia, canine anaplasmosis, canine babesiosis, canine lyme disease and canine leishmania can be realized by the detection card and the kit, and the detection sensitivity and the specificity are high. The detection card and the kit can be used for detecting canine Ehrlichia, canine anaplasmosis, canine babesiosis, canine lyme disease and canine leishmania. The detection card and the kit have the advantages that the detection card and the kit can be used for detecting canine Ehrlichia, canine anaplasmosis, canine babesiosis and canine leishmania;

The utility model discloses a mycoplasma detection kit which comprises a kit body, the top end of the kit body penetrates through the bottom end and is provided with a storage cavity, a reinforcing mechanism is inserted into the inner wall of the kit body, the reinforcing mechanism comprises a bottom plate, two fixing mechanisms are fixedly installed at the top end of the bottom plate, the reinforcing mechanism mainly comprises the bottom plate and a plurality of reinforcing rods, and the reinforcing rods are directly inserted into the inner wall of the kit body. According to the kit, the bottom plate can be firmly installed, the rigid strength of the kit body can be improved, the kit body is prevented from deforming, and therefore antivirus function reagents and mycoplasma antigen detection reagents are not prone to being squeezed to be damaged in the transportation and storage process, and the two fixing mechanisms are arranged on the bottom plate; a plastic bottle filled with disinfectant is jointly clamped in the two fixing mechanisms, it can be guaranteed that the plastic bottles of any specification can be effectively fixed through clamping of the fixing mechanisms, and the situation that the plastic bottles are collided and damaged due to transportation shaking is avoided.

The application discloses a kind of nanomaterial and its preparation method and application, the nanomaterial includes exosome and liposome;The exosome expresses immune checkpoint, the exosome is derived from brain glioma cell;The liposome is loaded with I type photosensitizer.The application is by PDT, immune checkpoint and brain glioma cell exosome antigen three tubes simultaneously to remodel tumor local immune microenvironment, greatly improve the efficiency of cancer immunotherapy, can activate strong anti brain glioma immune response and overcome immune escape.

Anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments, and their uses are provided.

The present invention provides anti-p75 neurotrophin receptor (p75NTR) antigen-binding proteins and protein-drug conjugates including an anti-p75NTR antigen-binding protein conjugated to a molecular cargo, as well as methods of treating diseases with such antigen-binding proteins and protein-drug conjugates.

Anti-IGF1R (Insulin-like Growth Factor 1 Receptor) antibodies, antigen binding fragments and uses thereof are provided.

The utility model discloses antibody-antigen reaction process display equipment, which comprises an exhibition stand, the exhibition stand comprises a support frame and an interaction table, the interaction table comprises an antibody turntable for representing antibodies and an antigen turntable for representing antigens, and the antibody turntable and the antigen turntable are arranged on the table top of the interaction table. A plurality of antibody tentacles representing different antibody types are arranged on the antibody turntable, and a plurality of antigen tentacles paired with the antibody tentacles are arranged on the antigen turntable; the interaction table further comprises a control system used for controlling the antigen rotating disc and the antibody rotating disc to rotate and enabling the antigen tentacles and the antibody tentacles to be paired. According to the utility model, visitors are enabled to participate in interactive experience through electromechanical interaction, the process of specific binding reaction between antigens and antibodies is intuitively felt and displayed, one antibody can only correspond to one specific antigen, and the knowledge of antigens and antibodies is deepened.

The invention provides a UBC-CK8 / 18 detection kit based on chemiluminescence, and the kit is characterized in that an antibody is immobilized through a streptavidin-biotin system to form a magnetic bead-biotinylated antibody-antigen-acridinium ester labeled antibody compound; after washing, the substrate solution excites the acridinium ester to generate a photon signal, and a relative luminescence unit (RLUs) is captured by a full-automatic chemiluminescence immunoassay instrument, so that rapid and low-cost clinical detection of bladder cancer is realized, and the detection performance is good.

The invention discloses a preparation and delivery strategy of a dendritic cell targeting vaccine. The vaccine delivery platform comprises: a) an antibody having a DC targeting function, which is selected from a targeting antibody of CD205; and b) a carrier antigen which is obtained by fusion expression of the antibody affinity molecule integrated with the non-natural amino acid and the antigen epitope or the antigen epitope splicing protein. According to the present invention, the CD205 antibody is adopted, the antigen epitope fusion protein containing the antibody affinity molecule is prepared through the UAA integration technology, and the fusion protein can be subjected to proximity induction coupling with the CD205 antibody through the UAA affinity molecule so as to achieve the efficient self-assembly of the CD205 and the antigen epitope; the vaccine delivery platform provided by the invention can realize accurate, efficient and switchable antigen delivery, provides a simple, convenient and flexible DC vaccine design strategy suitable for different antigens, and has a wide immunotherapy application prospect.

Disclosed herein are dimeric or pentameric antigen binding molecules and methods for making said dimeric or pentameric antigen binding molecules, wherein the isotype of the immunoglobulin monomers is IgA, 1gG4, or IgM. Also disclosed herein are methods of using dimeric antigen binding molecules to treat cancer associated with expression of an oncogene, gene overexpression, or a gene fusion.

This disclosure relates to anti-BTN3A (Butyrophilin-3A) antibodies, antigen-binding fragments, and the uses thereof.

The invention belongs to the technical field of molecular biology, and particularly relates to a recombinant vector for expressing OrfV truncated F1L protein, a strain and application of the recombinant vector. The preparation method comprises the following steps: truncating an F1L gene of an orf virus, introducing a His tag and a termination codon sequence, and constructing into a pYD1 plasmid to obtain a pYD1-F1L recombinant plasmid; and introducing the recombinant plasmid into competent cells of saccharomyces cerevisiae to obtain the recombinant yeast strain. According to the invention, the F1L gene of OrfV is truncated, so that the immunogenicity of the OrfV is effectively retained; the anchoring protein is displayed on the surface of the saccharomyces cerevisiae, so that the immune function of the saccharomyces cerevisiae can be developed; recombinant saccharomyces cerevisiae is adopted as a delivery carrier, the antigen protein can better play an immune role by means of the constant value of the recombinant saccharomyces cerevisiae in intestinal tracts, and meanwhile, the risk that the F1L protein is degraded by protease when being orally taken is further reduced. The invention provides a new direction for the development of OrfV oral vaccines.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to a follistatin polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to a follistatin polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.